Hepatic involvement in familial Mediterranean fever (FMF) ranges from a nonspecific increase in liver enzymes to cryptogenic cirrhosis, and the liver is mostly involved in patients bearing the M694V MEFV mutation in homozygosis. A 44-year-old Jewish woman with FMF developed nonalcoholic steatohepatitis during colchicine treatment (2,5 mg per day), confirmed by both elastography and liver biopsy. Therefore, combined therapy with the interleukin-1 (IL-1) blocking agent canakinumab (150 mg every four weeks) and colchicine (at a reduced dose of 1.5 mg per day) was started. Three months later, transaminases became normal, and after further six months, there was a marked improvement of liver fibrosis. IL-1 blockade has the power to halt or mitigate liver involvement in FMF patients. However, further experience is required to assess its therapeutic potential in the most severe patients with the hepatic disease who are partially responsive to long-term prophylaxis with colchicine.

Massaro, M. G., Pompili, M., Sicignano, L. L., Pizzolante, F., Verrecchia, E., Vecchio, F. M., Rigante, D., Manna, R., Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report, <<MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES>>, 2020; 2020 (12(1)): 1-5. [doi:10.4084/MJHID.2020.059] [http://hdl.handle.net/10807/160787]

Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report

Massaro, Maria Grazia;Pompili, Maurizio;Sicignano, Ludovico Luca;Pizzolante, Fabrizio;Vecchio, Fabio Maria;Rigante, Donato;Manna, Raffaele
2020

Abstract

Hepatic involvement in familial Mediterranean fever (FMF) ranges from a nonspecific increase in liver enzymes to cryptogenic cirrhosis, and the liver is mostly involved in patients bearing the M694V MEFV mutation in homozygosis. A 44-year-old Jewish woman with FMF developed nonalcoholic steatohepatitis during colchicine treatment (2,5 mg per day), confirmed by both elastography and liver biopsy. Therefore, combined therapy with the interleukin-1 (IL-1) blocking agent canakinumab (150 mg every four weeks) and colchicine (at a reduced dose of 1.5 mg per day) was started. Three months later, transaminases became normal, and after further six months, there was a marked improvement of liver fibrosis. IL-1 blockade has the power to halt or mitigate liver involvement in FMF patients. However, further experience is required to assess its therapeutic potential in the most severe patients with the hepatic disease who are partially responsive to long-term prophylaxis with colchicine.
2020
Inglese
Massaro, M. G., Pompili, M., Sicignano, L. L., Pizzolante, F., Verrecchia, E., Vecchio, F. M., Rigante, D., Manna, R., Improvement of liver involvement in familial Mediterranean fever after introduction of canakinumab: a case report, <<MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES>>, 2020; 2020 (12(1)): 1-5. [doi:10.4084/MJHID.2020.059] [http://hdl.handle.net/10807/160787]
File in questo prodotto:
File Dimensione Formato  
Massaro et al.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 476.68 kB
Formato Adobe PDF
476.68 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/160787
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact